Darren OW, Bhawanie Koonj Beharry, David Wetherell, Nathan Papa, Mahesha Weerakoon, Ania Sliwinski, Maurizio Brausi, Damien Bolton and Nathan Lawrentschuk
Bladder carcinoma is one of the commonest cancers in Australia and accounts for 2% of all cancers in Australia. According to the European Association of Urology (EAU) Guidelines, macroscopic Transurethral Resection (TUR) is the standard therapy for Ta and T1 papillary bladder tumours. The majority of bladder tumours are Non-Muscle Invasive (NMIBC) and are usually curable by endo-resection. However, despite the use of currently available equipment, the recurrence rate for bladder tumours remained very high.
Our aim is to highlight the new technologies available for the diagnosis and management of NMIBC. A review of the literature was performed using a PubMed search.
We conclude that new modalities in detection (Photodynamic Diagnosis (PDD) and Narrow Band Imaging (NBI)) and management (bipolar transurethral resection and en bloc resection) of bladder tumours might play a vital role in reducing the recurrence rate of bladder tumours.
分享此文章